EICHORCondition: First Progression of Glioblastoma · Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses. Treatment options include repeated surgery (if feasible), systemic therapy (bevacizumab, lomustine, temozolomide re-challenge), reirradiation and best supportive care. Currently, the superiority of combined chemoradiation versus chemotherapy alone remains unproven. Given that lomustine is the standard chemotherapeutic agent for the treatment of recurrent glioblastoma in Europe and the unclear efficacy of reirradiation, we want to explore whether combining lomustine and reirradiation may be a better treatment than lomustine alone. The results of the prospective randomized trial proposed here should demonstrate a significant improvement in overall survival when lomustine is combined with reirradiation in patients with recurrent glioblastoma compared to lomustine alone without adversely affecting quality of survival. The trial will be stopped based on overall survival in a preplanned futility and efficacy interim analysis.
This description comes directly from the study's public registry record.
EORTC · +3227741611 · eortc@eortc.org
Always discuss trial participation with your own doctor first.
| A.O Landeskrankenhaus - Innsbruck Universitaetsklinik | Innsbruck, Austria | Recruiting |
| Kepler University Hospital - Neuromed campus | Linz, Austria | Recruiting |
| Universitaetsklinikum Wien - AKH unikliniken | Vienna, Austria | Recruiting |
| AZORG | Aalst, Belgium | Recruiting |
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
| Grand Hopital de Charleroi - Site Les Viviers | Gilly, Belgium | Recruiting |
| U.Z. Leuven - Campus Gasthuisberg | Leuven, Belgium | Recruiting |
| Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus (previous GZA) | Wilrijk, Belgium | Recruiting |
| Masaryk Memorial Cancer Institute | Brno, Czechia | Recruiting |
| Aarhus University Hospitals - Region Midtjylland - Aarhus University Hospital-Skejby | Aarhus, Denmark | Recruiting |
| CHU d'Amiens - CHU Amiens Picardie - Site Sud | Amiens, France | Recruiting |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05904119